Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

  1. Vermersch, P.
  2. Oreja-Guevara, C.
  3. Siva, A.
  4. Van Wijmeersch, B.
  5. Wiendl, H.
  6. Wuerfel, J.
  7. Buffels, R.
  8. Kadner, K.
  9. Kuenzel, T.
  10. Comi, G.
Revue:
European Journal of Neurology

ISSN: 1468-1331,  1351-5101

Année de publication: 2022

Volumen: 29

Número: 3

Pages: 790-801

Type: Article

DOI: 10.1111/ENE.15171 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus